Publications

ProMab's goal to become one of the leading providers in antibody development, CAR-T research & immunotherapy space allows us to post our findings on accredited research publications. In addition, many of our clients and collaborators use our services to advance their own research. Visit this page to view some of our accomplishments and check the link below if you are interested in reading more. <p>&gt; PMC search</p>


  • A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells.

    Xi B, Berahovich R, Zhou H, Xu S, Wei Y, Guan J, Harto H, Guan J, Wu L, Santa Ana D, Cerignoil F, Lamarche B4, Abassi YA, Golubovskaya V.

    > View Article

  • Hypoxia Selectively Impairs CAR-T Cells In Vitro.

    Berahovich R, Liu X, Zhou H, Tsadik E, Xu S, Golubovskaya V, Wu L.

    > View Article

  • Generation of CAR-T Cells for Cancer Immunotherapy.

    Xu Q, Harto H, Berahovich R, Xu S, Zhou H, Golubovskaya V, Wu L.

    > View Article

  • CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth.

    Berahovich R, Zhou H, Xu S, Wei Y, Guan J, Guan J, Harto H, Fu S, Yang K, Zhu S, Li L, Wu L, Golubovskaya V.

    > View Article

  • GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.

    Golubovskaya VM, Berahovich R, Xu Q, Zhou H, Xu S, Guan J, Harto H, Li L, Wu L.

    > View Article

  • CAR-T Cell Therapy: From the Bench to the Bedside.

    Golubovskaya V.

    > View Article

  • CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth.

    Golubovskaya V, Berahovich R, Zhou H, Xu S, Harto H, Li L, Chao CC, Mao MM, Wu L.

    > View Article

  • FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells in vitro and in vivo.

    Berahovich R, Xu S, Zhou H, Harto H, Xu Q, Garcia A, Liu F, Golubovskaya VM, Wu L.

    > View Article

  • Major Highlights of the CAR-TCR Summit, Boston, 2016.

    Golubovskaya V, Berahovich R, Xu S, Harto H, Wu L.

    > View Article

  • Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy.

    Golubovskaya V, Wu L.

    > View Article

  • Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells in vitro and in vivo.

    Valentine M., Le Li,, Hua Zhou, Shirley Xu, Jinying Sun, Chengjing Liu, Hizkia Harto, Robert Berahovich, Vita Golubovskaya, Lijun Wu,

    > View Article

  • Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma

    Golubovskaya, V.; Zhou, H.; Li, F.; Valentine, M.; Sun, J.; Berahovich, R.; Xu, S.; Quintanilla, M.; Ma, M.C.; Sienkiewicz, J.; Huang, Y.; Wu, L.

    > View Article

  • Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma

    Golubovskaya, V.; Zhou, H.; Li, F.; Berahovich, R.; Sun, J.; Valentine, M.; Xu, S.; Harto, H.; Sienkiewicz, J.; Huang, Y.; Wu, L.

    > View Article

  • PLAP CAR-T cells mediate high specific cytotoxicity against colon cancer cells

    Li X, Berahovich R, Zhou H, Liu X, Li F, Xu S, Wei Y, Ouaret D, Bodmer W, Wu L, Golubovskaya V

    > View Article

  • Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth

    Wu L, Huang Y, Sienkiewicz J, Sun J, Guiang L, Li F, Yang L, Golubovskaya V.

    > View Article

  • mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth

    Golubovskaya V, Sienkiewicz J, Sun J, Huang Y, Hu L, Zhou H, Harto H, Xu S, Berahovich R, Bodmer W, Wu L. mRNA-Lipid Nanoparticle (LNP) Delivery of Humanized EpCAM-CD3 Bispecific Antibody Significantly Blocks Colorectal Cancer Tumor Growth. Cancers (Basel

    > View Article

  • CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo

    Golubovskaya V, Sienkiewicz J, Sun J, Zhang S, Huang Y, Zhou H, Harto H, Xu S, Berahovich R, Wu L. CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo. Int J Mol Sci. 2023 Aug 29;24(17):13364. doi: 10.3390/ijms241713364. PMI

    > View Article